Federal government relations and advocacy regarding regulations under the Patented Medicine Prices Review Board (and its impact to drugs for rare diseases), national pharmacare policy and implementation, and the development of a federal strategy for drugs for rare diseases.
Build awareness with decision makers on ADHD, the lack of broad-based screening, and advocate for the implementation of programs to improve diagnosis and support of those living with ADHD.